Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is an aldosterone antagonist, potassium-sparing diuretic with actions and uses similar to those of spironolactone. Both are prodrugs that are metabolized to canrenone. It is used in the treatment of edema associated with heart failure or liver disease and in primary hyperaldosteronism. intravenous administration.
At the date of the last update we did not find any published data on its excretion in breast milk.
The paucity of known pharmacokinetic data does not allow predictions about its possible excretion in breast milk.
The literature on this drug is scarce and it is sold in few countries.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.